{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:01:35Z","timestamp":1785214895877,"version":"3.55.0"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1055\/a-2697-1845","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:32:30Z","timestamp":1785191550000},"page":"835-842","source":"Crossref","is-referenced-by-count":0,"title":["H\u00e4matologische Nebenwirkungen der Zell- und Immuntherapie"],"prefix":"10.1055","volume":"151","author":[{"given":"Romy L.","family":"Zuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Rejeski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc M.","family":"Berclaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"K Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"issue":"10","key":"ref2","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s00520-025-09952-2","article-title":"Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"33","author":"MT Cruz Carreras","year":"2025","journal-title":"Support Care Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"K Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/bcp.14433","article-title":"Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy","volume":"86","author":"BL Mangan","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40164-024-00573-9","article-title":"New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies","volume":"13","author":"Y Yang","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/cancers17020282","article-title":"Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies","volume":"17","author":"A Bangolo","year":"2025","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"BJ Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"J Haanen","year":"2022","journal-title":"Annals of Oncology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"s1169","DOI":"10.5530\/ijper.58.4s.115","article-title":"Immune Checkpoint Inhibitors for Cancer Therapy: Status and Future Directions","volume":"58","author":"MS Alam","year":"2024","journal-title":"Indian Journal of Pharmaceutical Education and Research"},{"issue":"10","key":"ref11","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Special Report Introduction and state of the art","volume":"142","author":"K Rejeski","year":"2023","journal-title":"Blood"},{"issue":"07","key":"ref12","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1182\/blood.2025028833","article-title":"T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy","volume":"146","author":"K Rejeski","year":"2025","journal-title":"Blood"},{"issue":"01","key":"ref13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40164-024-00573-9","article-title":"New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies","volume":"13","author":"Y Yang","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"K Rejeski","year":"2021","journal-title":"Blood"},{"issue":"25","key":"ref15","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"MH Kroll","year":"2022","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2019000962","article-title":"Mechanisms and management of CAR T toxicity","volume":"14","author":"CJ Ferreri","year":"2024","journal-title":"Front Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41408-022-00741-2","article-title":"Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma","volume":"12","author":"KC Miller","year":"2022","journal-title":"Blood Cancer J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline","volume":"39","author":"BD Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41409-024-02233-2","article-title":"Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma","volume":"59","author":"M Mohan","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1678754","article-title":"Severe immunotherapy-related autoimmune hemolytic anemia induced by toripalimab in a patient with deficient mismatch repair colorectal cancer: a case report and literature review","volume":"12","author":"X Ma","year":"2025","journal-title":"Front Med (Lausanne)"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2697-1845.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:46:36Z","timestamp":1785213996000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2697-1845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":19,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,7,27]]},"published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2697-1845","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}